This technology has vast potential to help patients but remains underutilized and underappreciated. The tools are there. What’s lacking are harmonized controls, regulatory guidelines and database ...
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback